Trial · NCT02893553
The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury
NCT02893553, Phase 2, Completed, James J. Peters Veterans Affairs Medical Center; results first posted 2024-10-01
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury. Trials, record NCT02893553. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02893553
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury
- NCT number
- NCT02893553
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 21 participants, actual
- Lead sponsor
- James J. Peters Veterans Affairs Medical Center
- Conditions
- Spinal Cord Injury, Autonomic Dysreflexia, Baroreceptor Integrity, Sympathetic Integrity, Vagal Integrity, Autonomic Integrity, Hypotensive, Cognitive Function, Cerebral Blood Flow, Blood Pressure
- Interventions
- Midodrine Hydrochloride, Pyridostigmine Bromide, Mirabegron, Placebo
- First posted
- 2016-09-08
- Last updated
- 2024-10-01
- Results first posted
- 2024-10-01
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Systolic Blood Pressure | 4 hours | Seated systolic blood pressure following intervention administration. |
| Primary | Number of Participants With Normal Blood Pressure Readings | 4 hours | Number of participants with a systolic blood pressure readings between 111-139 mmHg in response to each of the four conditions: 1. Placebo 2. Midodrine 3. Mirabegron 4. Pyridostigmine |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Systolic Blood Pressure | 4 hours | Means are compared between medications and placebo of study 2, regardless of dose, as pre-specified in the study protocol. | mmHg | MEAN |
| PRIMARY | Number of Participants With Normal Blood Pressure Readings | 4 hours | Data are compared between medications and placebo of study 2, regardless of dose, as pre-specified in the study protocol. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Systolic Blood Pressure | Study 2: Placebo | 93.21 | Standard Deviation 9.01 | mmHg | |
| Systolic Blood Pressure | Study 2: Midodrine | 107.00 | Standard Deviation 11.07 | mmHg | |
| Systolic Blood Pressure | Study 2: Mirabegron | 95.8 | Standard Deviation 9.5 | mmHg | |
| Systolic Blood Pressure | Study 2: Pyridostigmine | 93.84 | Standard Deviation 9.69 | mmHg | |
| Number of Participants With Normal Blood Pressure Readings | Study 2: Placebo | 4 | Participants | ||
| Number of Participants With Normal Blood Pressure Readings | Study 2: Midodrine | 14 | Participants | ||
| Number of Participants With Normal Blood Pressure Readings | Study 2: Mirabegron | 6 | Participants | ||
| Number of Participants With Normal Blood Pressure Readings | Study 2:Pyridostigmine | 5 | Participants |
Source ClinicalTrials.gov
Participant flow26
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Study 1 | STARTED | Study 1 | 21 | |
| Study 1 | Midodrine (Low) | Study 1 | 19 | |
| Study 1 | Midodrine (Medium) | Study 1 | 6 | |
| Study 1 | Midodrine (High) | Study 1 | 0 | |
| Study 1 | Mirabegron (Low) | Study 1 | 19 | |
| Study 1 | Mirabegron (Medium) | Study 1 | 15 | |
| Study 1 | Mirabegron (High) | Study 1 | 8 | |
| Study 1 | Pyridostigmine (Low) | Study 1 | 19 | |
| Study 1 | Pyridostigmine (Medium) | Study 1 | 10 | |
| Study 1 | Pyridostigmine (High) | Study 1 | 5 |
1 to 10 of 26Source ClinicalTrials.gov
See all 26 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals30
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Midodrine (Low) | 0 | 19 |
| Total, all-cause mortality | Midodrine (Mid) | 0 | 6 |
| Total, all-cause mortality | Midodrine (High) | 0 | 0 |
| Total, all-cause mortality | Mirabegron (Low) | 0 | 19 |
| Total, all-cause mortality | Mirabegron (Mid) | 0 | 15 |
| Total, all-cause mortality | Mirabegron (hi) | 0 | 8 |
| Total, all-cause mortality | Pyridostigmine (Low) | 0 | 19 |
| Total, all-cause mortality | Pyridostigmine (Mid) | 0 | 10 |
| Total, all-cause mortality | Pyridostigmine (hi) | 0 | 5 |
| Total, all-cause mortality | Placebo | 0 | 16 |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02893553
GET https://conductscience.org/api/trials/v1/NCT02893553/flow?page=2